LinkedIn Profile

Access Rogne Bioscience historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:rognebioscience-2 2660571 May 31st, 2019 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology May 31st, 2019 01:53PM May 31st, 2019 01:53PM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Open Open Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Mar 23rd, 2018 12:00AM Rogne Bioscience, Inc. 34 0.00 Open Biotechnology Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 17th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 16th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 15th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 14th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 13th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 12th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 11th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology
private:rognebioscience-2 2660571 Feb 10th, 2018 12:00AM Rogne Bioscience, Inc. 35 0.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com Rogne Bioscience Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.